Status:

NOT_YET_RECRUITING

The Anti-reflux Effect of Double-flap Technique in Laparoscopic Proximal Gastrectomy.

Lead Sponsor:

Changzhi People's Hospital Affiliated to Changzhi Medical College

Conditions:

Proximal Early Gastric Cancer

Eligibility:

All Genders

20-80 years

Phase:

NA

Brief Summary

This study is a multicenter, open-label, prospective, randomized parallel-controlled trial. The purpose is to explore whether the incidence rate of reflux esophagitis (RE) within 12 months after surge...

Detailed Description

This study will enroll patients with proximal gastric cancer scheduled to undergo laparoscopic proximal gastrectomy. The patients will be randomly divided into two groups. One group will undergo lapar...

Eligibility Criteria

Inclusion

  • Age between 20 and 80 years, regardless of gender;
  • Patients diagnosed with gastric cancer through tissue biopsy;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  • American Society of Anesthesiologists (ASA) classification of I to III;
  • Acceptable for laparoscopic proximal gastrectomy with preoperative examinations (based on endoscopic ultrasound and/or contrast-enhanced computed tomography of the thorax and abdomen) confirming the following oncological features:
  • Primary tumor located in the upper part of the stomach (proximal 1/3 of the stomach) or gastroesophageal junction; Length of esophageal invasion ≤ 1 cm, tumor maximum diameter ≤ 4 cm; Preoperative staging T1-3N0M0 (based on AJCC 8th edition TNM clinical staging);
  • Voluntary signing of informed consent.

Exclusion

  • Received preoperative chemotherapy, radiotherapy, targeted therapy, or immunotherapy;
  • Presence of contraindications to surgery;
  • Multiple malignant lesions in the stomach;
  • Presence of other malignancies that may affect the preservation of stomach function;
  • Previous upper abdominal surgery (excluding cholecystectomy);
  • Preoperative examination reveals active peptic ulcer;
  • Patients who have received or are currently receiving treatment for systemic inflammatory diseases;
  • Pregnant or breastfeeding women;
  • Conditions deemed unsuitable for participation in this study by the investigator.

Key Trial Info

Start Date :

August 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2027

Estimated Enrollment :

244 Patients enrolled

Trial Details

Trial ID

NCT06511609

Start Date

August 1 2024

End Date

July 31 2027

Last Update

July 22 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.